NASDAQ$ALMR

Alamar Biosciences, Inc · Q1 2026 earnings

Q1 2026 earnings ·

Briefing

Alumis reported Q1 2026 total revenue of $26.0M with a net loss of $21.3M, or $1.74 per share, ahead of its April 2026 IPO.

For the quarter ended March 31, 2026, Alumis reported total revenue of $26.0 million versus $13.1 million a year ago, with product revenue of $21.3 million. Net loss was $21.3 million, or $1.74 per diluted share, compared with a $7.7 million loss and $0.68 per share in Q1 2025. The company completed its IPO in April 2026.

  • Total revenue $26.0M (+99% YoY); product revenue $21.3M.
  • Net loss $21.3M, or $(1.74) per share.
  • IPO completed April 2026 after quarter end.

Headline financials

Total Revenue

$26M

No prior period
EPS (adj)

-$1.74

No prior period
Capital Expenditures

-$600K

No prior period
Free Cash Flow

-$20.9M

No prior period
Net Income

-$21.3M

No prior period
Operating Income

-$12.3M

No prior period
Gross Profit

$14.5M

No prior period
Cash & Equivalents

$64.6M

No prior period
Total Assets

$186M

No prior period

Revenue & EPS history

Alamar Biosciences, Inc · Revenue · Quarterly

$26M

Q1 2026

Forward guidance

Pre-commercial biotech; no annual revenue or EPS guidance in the 10-Q.

Tailwinds

  • Product revenue ramp ahead of IPO.

Headwinds

  • Operating loss widened with R&D and G&A investment.

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro